

Comprehensive Relationships With Industry and Other Entities—AHA/ACC 2017 Update of ST-Elevation Myocardial Infarction and Non–ST-Elevation Myocardial Infarction Measures

Committee Member	Employment	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Jneid Hani, <i>Chair</i>	Baylor College of Medicine — Associate Professor of Medicine; Director of Interventional Cardiology Research The Michael DeBakey VA Medical Center— Director of Interventional Cardiology	None	None	None	None	None	None
Daneil Addison	Fellow at Massachusetts General Hospital	None	None	None	None	None	None
Deepak L. Bhatt	Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart & Vascular Center; Harvard Medical School — Professor of Medicine	<ul style="list-style-type: none"> • Duke Clinical Research Institute: Ferring Pharmaceuticals • Duke Clinical Research Institute: Novartis • Duke Clinical Research Institute: Bristol-Myers Squibb/Pfizer • Duke Clinical 	None	None	<ul style="list-style-type: none"> • Amarin† • Amgen† • Astra Zeneca† • BIOFLOW-V (Biotronik)-clinical trial • Bristol Myers Squibb† • CardioMEMs HF System Post Approval Study (St. Jude Medical clinical trial) • Eisai† • Ethicon† 	<ul style="list-style-type: none"> • ACC JACC Associate Editor† • ACC,org Senior Associate Editor† • AHA GWTG Chair* • Belvoir Publications† • Cardax* • Clinical Cardiology* • Duke Clinical Research Institute Data Safety Monitoring Board • Harvard Clinical Research Institute: 	None

Committee Member	Employment	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
		Research Institute: Eli Lilly <ul style="list-style-type: none"> • Elsevier Practice Update Cardiology† • Population Health Research Institute 			<ul style="list-style-type: none"> • EVOLVE Short DAPT Study (Boston Scientific) • Flowco* • Forest Laboratories† • Ischemix† • Medtronic† • Merck and Co, Inc* • Pfizer† • PLxPharma* • Roche† • Sanofi Aventis† • Takeda* • The Medicines Company† 	Boehringer Ingelheim <ul style="list-style-type: none"> • Harvard Clinical Research Institute: St. Jude Data Safety Monitoring Board • HMP Communications (Journal of Invasive Cardiology Editor in Chief) † • Journal of Invasive Cardiology† • Mayo Clinic Data Safety Monitoring Board • Medscape Cardiology* • Merck & Co., Inc. Planning Committee for Clinical Study* • Novartis • Regado Biosciences* • Society of Chest Pain Centers Board of Directors† • Slack Publications /Cardiology Research Foundation† • VA Healthcare System* • WebMD† 	
Gregg Fonarow	Ahmanson-UCLA Cardiomyopathy Center Division of Cardiology — Director of UCLA's Cardiology Fellowship	<ul style="list-style-type: none"> • Amgen • Boston Scientific • Janssen • Johnson&Johnson • Medicines Company • Medtronic • Novartis† 	None	None	<ul style="list-style-type: none"> • Medtronic • NHLBI † • NIH/NIAID † • Novartis† 	<ul style="list-style-type: none"> • ACCF/AHA Task Force on Data Standards* • ACCF/AHA Task Force on Performance Measures* • ACTION Registry GWTG Steering Committee Chair* • AHA Consumer Health Quality Coordinating 	None

Committee Member	Employment	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Program	<ul style="list-style-type: none"> • Takeda • Janssen • St. Jude Medical • ZS Pharma 				Committee* <ul style="list-style-type: none"> • AHA Manuscript Oversight Committee* • GWTG Steering Committee (PRT)* • Medtronic- IMPROVE HF Steering Committee* • JAMA Cardiology* 	
Sana Gokak	ACC/AHA	None	None	None	None	None	None
Kathleen L. Grady	Northwestern University Feinberg School of Medicine — Professor of Surgery and Medicine; and Administrative Director for Heart Failure	None	None	None	<ul style="list-style-type: none"> • NIA† • NHLBI† 	<ul style="list-style-type: none"> • AHA* 	None
Lee A. Green	University of Michigan — Professor Emeritus	None	None	None	<ul style="list-style-type: none"> • Alberta Innovates Health Solutions† 	None	None
Paul Heidenreich	Stanford VA Palo Alto Health Care System —Professor of Medicine	None	None	None	None	None	None
P. Michael Ho	VA Eastern Colorado Health Care System University of Colorado School of	<ul style="list-style-type: none"> • Anthem, Inc.† • Janssen Pharmaceuticals, Inc† 	None	None	None	None	None

Committee Member	Employment	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Medicine — Associate Professor of Medicine	<ul style="list-style-type: none"> • Premier, Inc.† • Telligen* 					
Corrine Jurgens	Stony Brook University — Associate Professor	None	None	None	None	None	None
Marjorie King	Assistant Professor of Medicine at Columbia University Medical Center and Chief Medical Officer at Helen Hayes Helen Hayes Hospital	<ul style="list-style-type: none"> • Island Peer Review Organization† 	None	None	None	None	None
Dharam Kumbhani	UT Southwestern Medical Center — Assistant Professor of Medicine	<ul style="list-style-type: none"> • ACC† 	None	None	None	None	None
Samir Pancholy	The Wright Center for Graduate Medical Education	None	<ul style="list-style-type: none"> • Metronic • Pfizer† • Terumo Medical 		<ul style="list-style-type: none"> • Duke Clinical Research Institute Odyssey Outcomes Trial 	None	

This table represents the relationships of committee members with industry and other entities that were reported by authors to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of \$5,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.

*No financial relationship †Significant (greater than \$5,000) relationship.

ACC indicates American College of Cardiology; AHA, American Heart Association; BIOFLOW-V, A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V; EVOLVE DAPT, A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System; GWTG; Get With The Guidelines; HF, heart failure; IMPROVE HF, Improving evidence-based care for heart failure in outpatient cardiology practices; JACC, Journal of the American College of Cardiology; JAMA; Journal of the American Medical Association; NHLBI, National Health, Lung, and Blood Institute; NIA, National Institute on Aging; NIH/NIAID, National Institutes of Health\National Institute of Allergy and Infectious Disease; UCLA; University of California Los Angeles; UT, University of Texas; and VA, Veterans Affairs.